Dr. Mary Hammes DO is a clinical Nephrologist certified by the American Board of Internal Medicine for over 30 years.She has an interest in chronic out-patient hemodialysis and is the Medical Director for a large outpatient hemodialysis unit. Her clinical effort is focused on improving the lives and outcomes of patients with End Stage Kidney Disease.
Dr Hammes conducts research focused on the vascular access used by patients to receive their hemodialysis. This is considered their lifeline and is an important aspect of their care. Her primary research goal is to investigate the science behind vascular access failure specifically stenosis and thrombosis which will lead to improved care for patients on hemodialysis. In collaboration with other scientists at the University of Chicago, she has developed a novel patient specific milli-fluidic model to study the flow through veins used for dialysis. She has numerous publications on this topic, has been awarded research grants and directs a monthly dialysis access conference. Her work had brought together multi-discipline collaboration in medicine, surgery, radiology, epidemiology, bioengineering, and genetics with the aim to understand the choice of access placement, mechanism of access failure, direct treatment and improve overall morbidity and mortality of patients with end stage renal disease requiring hemodialysis.
The FACT : Use of a novel intermittent pneumatic compression device to promote pre-surgery arm vein dilation in patients with chronic renal failure.
The FACT : Use of a novel intermittent pneumatic compression device to promote pre-surgery arm vein dilation in patients with chronic renal failure. J Vasc Access. 2023 Sep; 24(5):911-919.
PMID: 34789025
Intradialytic Hypotension: Is Midodrine the Answer?
Intradialytic Hypotension: Is Midodrine the Answer? Am J Nephrol. 2018; 48(5):378-380.
PMID: 30423560
Are Non-Newtonian Effects Important in Hemodynamic Simulations of Patients With Autogenous Fistula?
Are Non-Newtonian Effects Important in Hemodynamic Simulations of Patients With Autogenous Fistula? J Biomech Eng. 2017 Apr 01; 139(4).
PMID: 28249082
When Is the Right Time for Arteriovenous Fistula Placement in Patients with End-Stage Renal Disease?
When Is the Right Time for Arteriovenous Fistula Placement in Patients with End-Stage Renal Disease? Am J Nephrol. 2017; 45(4):353-355.
PMID: 28301841
Importance of the Endothelium in Arteriovenous Fistula Outcomes.
Importance of the Endothelium in Arteriovenous Fistula Outcomes. Am J Nephrol. 2016; 44(6):426-427.
PMID: 27784006
Hemodynamic and biologic determinates of arteriovenous fistula outcomes in renal failure patients.
Hemodynamic and biologic determinates of arteriovenous fistula outcomes in renal failure patients. Biomed Res Int. 2015; 2015:171674.
PMID: 26495286
Morphometric and histological parameters in veins of diabetic patients undergoing brachiocephalic fistula placement.
Morphometric and histological parameters in veins of diabetic patients undergoing brachiocephalic fistula placement. Hemodial Int. 2015 Oct; 19(4):490-8.
PMID: 25731584
Asymmetric dimethylarginine and whole blood viscosity in renal failure.
Asymmetric dimethylarginine and whole blood viscosity in renal failure. Clin Hemorheol Microcirc. 2015; 59(3):245-55.
PMID: 24840340
Whole blood viscosity: Effect of hemodialysis treatment and implications for access patency and vascular disease.
Whole blood viscosity: Effect of hemodialysis treatment and implications for access patency and vascular disease. Clin Hemorheol Microcirc. 2012; 51(4):265-75.
PMID: 22337820
Medical complications in hemodialysis patients requiring vascular access radiology procedures.
Medical complications in hemodialysis patients requiring vascular access radiology procedures. Semin Intervent Radiol. 2004 Jun; 21(2):105-10.
PMID: 21331116